These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9453273)

  • 1. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig).
    Proietti-Cecchini A; Afra J; Schoenen J
    Cephalalgia; 1997 Dec; 17(8):849-54; discussion 799. PubMed ID: 9453273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Auditory evoked potentials in the assessment of central nervous system effects of antimigraine drugs.
    Roon KI; Sándor PS; Schoonman GG; Lamers FP; Schoenen J; Ferrari MD; van Dijk JG
    Cephalalgia; 1999 Dec; 19(10):880-5. PubMed ID: 10668107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
    Martin GR
    Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
    Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
    Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan.
    Edmeads JG; Millson DS
    Cephalalgia; 1997 Oct; 17 Suppl 18():41-52. PubMed ID: 9399016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of zolmitriptan (Zomig) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine.
    Hughes AM; Dixon R; Dane A; Kemp J; Cummings L; Yates RA
    Cephalalgia; 1999 Mar; 19(2):100-6; discussion 73. PubMed ID: 10214535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
    Schoenen J; Sawyer J
    Cephalalgia; 1997 Oct; 17 Suppl 18():28-40. PubMed ID: 9399015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin 5HT1B/1D receptor agonists abolish NMDA receptor-evoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices.
    Stepień A; Chalimoniuk M; Strosznajder J
    Cephalalgia; 1999 Dec; 19(10):859-65. PubMed ID: 10668104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
    Hoskin KL; Goadsby PJ
    Exp Neurol; 1998 Mar; 150(1):45-51. PubMed ID: 9514827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
    Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists.
    Ferrari MD
    Neurology; 1997 Mar; 48(3 Suppl 3):S21-4. PubMed ID: 9071266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers.
    Mercer AJ; Lamb RJ; Rolan PE; Gibbens M; Posner J
    Psychopharmacology (Berl); 1998 Dec; 140(4):398-404. PubMed ID: 9888613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?
    Goadsby PJ; Hoskin KL
    Pain; 1996 Oct; 67(2-3):355-9. PubMed ID: 8951929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).
    Peck RW; Seaber EJ; Dixon R; Gillotin CG; Weatherley BC; Layton G; Posner J
    Br J Clin Pharmacol; 1997 Dec; 44(6):595-9. PubMed ID: 9431839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
    Rolan P
    Cephalalgia; 1997 Oct; 17 Suppl 18():21-7. PubMed ID: 9399014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat.
    Goadsby PJ; Knight YE
    Cephalalgia; 1997 May; 17(3):153-8. PubMed ID: 9170337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical applications of zolmitriptan (Zomig, 311C90).
    Lipton RB; Stewart WF
    Cephalalgia; 1997 Oct; 17 Suppl 18():53-9. PubMed ID: 9399017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group.
    Zagami AS
    Neurology; 1997 Mar; 48(3 Suppl 3):S25-8. PubMed ID: 9071267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.
    Rapoport AM; Ramadan NM; Adelman JU; Mathew NT; Elkind AH; Kudrow DB; Earl NL
    Neurology; 1997 Nov; 49(5):1210-8. PubMed ID: 9371896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period.
    Thomsen LL; Dixon R; Lassen LH; Gibbens M; Langemark M; Bendtsen L; Daugaard D; Olesen J
    Cephalalgia; 1996 Jun; 16(4):270-5. PubMed ID: 8792040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.